Is delayed facilitated percutaneous coronary intervention better than immediate in reperfused myocardial infarction? Six months follow up findings.

Abstract:

BACKGROUND:There are several new strategies proposed to improve the outcome of patients with ST-elevation myocardial infarction (STEMI). One approach is the resurgent use of facilitated percutaneous coronary interventions (PCI). Until recently, deciding whether immediate PCI after combined treatment (facilitated PCI) is more appropriate than delayed PCI (short time) has not been investigated. The aim of this study, therefore, was to investigate the outcomes in patients initially successfully treated pharmacologically and immediate PCI < 2 hr, and in patients initially successfully treated with pharmacological therapy and with delayed PCI (12-72 h). METHODS:451 reperfused STEMI patients, aged 18 to 75 years, class I-II Killip, with an acceptable echocardiographic window and admitted within 12 hs of the onset of symptoms were randomized into two groups. All patients had to have successful reperfusion, to receive the combination of a standard tirofiban infusion or abciximab plus half dose rtPA. Thereafter, patients were sub-grouped as follows:group 1 (immediate PCI) patients had PCI within 2 h; and group 2 (delayed PCI) patients in which PCI was performed after 12 hs and within 72 hs. RESULTS:The 225 reperfused (immediate-PCI) and 226 reperfused (delayed-PCI) patients (time from randomization to PCI 165 +/- 37 min in immediate PCI versus 45.1 +/- 20.2 h in delayed PCI group) showed similar results in ejection fraction, CK release and patency of the IRA. In addition, the delayed PCI group showed a significant reduction in ischemic events, restenosis and bleedings (P = 0.005, 0.01, 0.01 respectively) and significant reduced angiographic evidence of thrombus formation in the infarction-related artery (IRA) (p = 0.001). CONCLUSION:Our data suggest the safety and possible use of delayed facilitated PCI in patients with STEMI, and that delayed PCI in patients treated with combined lytic and IIb/IIIa inhibitors appears to be as effective and possibly superior (reduced ischemic events and repeat PCI) as immediate PCI. The patients in this study were successfully reperfused, with TIMI-3 flow and our data may not apply to patients with TIMI 0-2 flow. This strategy could allow transferring the reperfused patients and performing PCI after hours < 72 hours and not immediately, thereby reducing the number of urgent PCI and costs, obtaining similar results, but mostly causing less discomfort to the patient. Our results had to be interpreted with caution, because current guidelines do not recommend the combined therapy, but suggest further studies. The study was aimed to investigate the outcomes in patients initially successfully treated pharmacologically and immediate PCI < 2 h, and in patients initially successfully treated with pharmacological therapy and delayed PCI (12-72 h). All patients had to have successful reperfusion, to receive the combination of a standard abciximab or tirofiban infusion plus half dose rtPA. Similar results were observed in both groups. Delayed PCI group showed a significant lower incidence in restenosis (0.01), minor bleedings (0.005), ischemic events (0.01) and a reduced angiographic evidence of thrombus formation in IRA (0.001). Our data suggest the safety and possible use of delayed facilitated PCI in patients with STEMI. Our results had to be interpreted with caution, because current guidelines do not recommend the combined therapy, but suggest further studies.

journal_name

J Thromb Thrombolysis

authors

Di Pasquale P,Cannizzaro S,Parrinello G,Giambanco F,Vitale G,Fasullo S,Scalzo S,Ganci F,La Manna N,Sarullo F,La Rocca G,Paterna S

doi

10.1007/s11239-006-5733-z

subject

Has Abstract

pub_date

2006-04-01 00:00:00

pages

147-57

issue

2

eissn

0929-5305

issn

1573-742X

journal_volume

21

pub_type

杂志文章,随机对照试验
  • Venous thromboembolism 2011-2018 in Stockholm: a demographic study.

    abstract::Venous thromboembolism (VTE) is an important cause of morbidity and mortality in Western countries. The incidence rate of VTE is estimated at 1-2 cases per 1000 annually. This study was a population-based cohort study of previously treatment naïve patients with a first occurrence of venous thromboembolism (VTE), using...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-019-01966-y

    authors: Wändell P,Forslund T,Danin Mankowitz H,Ugarph-Morawski A,Eliasson S,Braunschwieg F,Holmström M

    更新日期:2019-11-01 00:00:00

  • Hyperthyroidism is associated with shortened APTT and increased fibrinogen values in a general population of unselected outpatients.

    abstract::Although clinical evidence supports a plausible association between thyroid disorders and venous thrombosis, reliable evidence is so far lacking on the potential biological mechanisms and neither temporary nor permanent thromboembolic risk factors were constantly identified. We performed a 2-years retrospective analys...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-008-0269-z

    authors: Lippi G,Franchini M,Targher G,Montagnana M,Salvagno GL,Guidi GC,Favaloro EJ

    更新日期:2009-10-01 00:00:00

  • Persisting autoimmune heparin-induced thrombocytopenia after elective abdominal aortic aneurysm repair: a case report.

    abstract::Persisting heparin-induced thrombocytopenia (HIT) is characterized by ongoing thrombocytopenia more than 7 days after stopping heparin. It is part of cases referred to as autoimmune HIT (aHIT). In contrast to typical HIT cases, aHIT involves heparin-independent platelet activation mechanism highlighted by a strongly p...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-020-02062-2

    authors: Roberge G,Tritschler T,MacGillivray C,Dufresne L,Nagpal SK,Scarvelis D

    更新日期:2020-10-01 00:00:00

  • Acquired thrombotic thrombocytopenic purpura: puzzles, curiosities and conundrums.

    abstract::We report a case of acquired thrombotic thrombocytopenic purpura (TTP) in a 34-year old patient with a prior diagnosis of systemic lupus erythematosis (SLE) who was recently started on hydroxychloroquine. Presenting symptoms included fevers, sore throat and productive cough with progressive weakness, dyspnea on exerti...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-010-0517-x

    authors: Mar N,Mendoza Ladd A

    更新日期:2011-01-01 00:00:00

  • Challenges and benefits of an inpatient anticoagulation service: one hospital's experience.

    abstract::While outpatient anticoagulation services (AMS) have existed extensively for a number of years, inpatient AMS have only recently begun to be implemented on a widespread basis. This is in direct response to anticoagulation regulations set forth by entities such as the Joint Commission (TJC) and the Centers for Medicare...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-011-0563-z

    authors: Burnett A,D'Angio R,Earl LE,Garcia D

    更新日期:2011-04-01 00:00:00

  • Venous thromboembolism: patient awareness and education in the pre-operative assessment clinic.

    abstract::Each year venous thromboembolism (VTE) causes up to 60,000 deaths in the UK, many resulting from hospital-acquired thromboses following elective surgery. National Institute for Health and Clinical Excellence (NICE) guidelines state that all elective surgical patients should receive verbal and written information pre-o...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章

    doi:10.1007/s11239-015-1224-4

    authors: Haymes A

    更新日期:2016-04-01 00:00:00

  • Point-of-care testing of coagulation in patients treated with edoxaban.

    abstract::Edoxaban, alongside other direct oral anticoagulants (DOAC), is increasingly used for prevention of thromboembolism, including stroke. Despite DOAC therapy, however, annual stroke rate in patients with atrial fibrillation remains 1-2%. Rapid exclusion of relevant anticoagulation is necessary to guide thrombolysis or r...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-020-02143-2

    authors: Härtig F,Birschmann I,Peter A,Hörber S,Ebner M,Sonnleitner M,Spencer C,Bombach P,Stefanou MI,Kuhn J,Mengel A,Ziemann U,Poli S

    更新日期:2020-10-01 00:00:00

  • Circulating lipid levels and risk of coronary artery disease in a large group of patients undergoing coronary angiography.

    abstract::A main underlying pathology of coronary artery disease is the deposition of cholesterol in the arteries supplying blood to the heart that leads to stenosis and myocardial infarction. We tested if dyslipidemia is a risk factor for coronary artery disease in the Lebanese population, and studied the role of the total cho...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1007/s11239-014-1069-2

    authors: Platt DE,Ghassibe-Sabbagh M,Youhanna S,Hager J,Cazier JB,Kamatani Y,Salloum AK,Haber M,Romanos J,Doueihy B,Mouzaya F,Kibbani S,Sbeite H,Deeb ME,Chammas E,El Bayeh H,Khazen G,Gauguier D,Zalloua PA,Abchee AB,FGENTCA

    更新日期:2015-01-01 00:00:00

  • Implications of an inpatient warfarin dosing nomogram on safety outcomes post-discharge.

    abstract::Many hospitals have implemented warfarin dosing nomograms to improve patient safety. To our knowledge, no study has assessed the impact inpatient warfarin initiation has in both medical and surgical patients, on safety outcomes post discharge. To evaluate the impact of a suggested institutional nomogram for the initia...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-016-1462-0

    authors: Chamoun N,Macías CG,Donovan JL,Klugman R,Gore J,Salameh P,Tran MT

    更新日期:2017-05-01 00:00:00

  • Incidence and outcomes of catheter related thrombosis (CRT) in patients with acute leukemia using a platelet-adjusted low molecular weight heparin regimen.

    abstract::Patients with acute leukemia frequently develop catheter-related thrombosis (CRT) despite concurrent thrombocytopenia. The incidence, treatment and outcomes of this complication are poorly documented. We undertook this study to determine the incidence of CRT in patients with acute leukemia and assess the safety and ef...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-018-1711-5

    authors: Htun KT,Ma MJY,Lee AYY

    更新日期:2018-10-01 00:00:00

  • Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial.

    abstract::Warfarin is dependent on multiple hepatic enzymes for metabolism while apixaban is a substrate for P-glycoprotein (P-gp) transport and hepatic CYP3A4 metabolism. The aim of this analysis was to assess the impact of interacting medication use on the treatment effects of apixaban versus warfarin. Outcomes were compared ...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s11239-019-01823-y

    authors: Washam JB,Hohnloser SH,Lopes RD,Wojdyla DM,Vinereanu D,Alexander JH,Gersh BJ,Hanna M,Horowitz J,Hylek EM,Xavier D,Verheugt FWA,Wallentin L,Granger CB,ARISTOTLE Committees and Investigators.

    更新日期:2019-04-01 00:00:00

  • Anticoagulant therapy management of venous thromboembolism recurrence occurring during anticoagulant therapy: a descriptive study.

    abstract::Limited evidence exists regarding management of recurrent venous thromboembolism (VTE) that occurs during anticoagulant therapy. We aimed to describe patient characteristics, drug therapy management, and outcomes of patients with VTE recurrence during anticoagulant therapy. We identified 30 relevant episodes of VTE re...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-021-02377-8

    authors: Lai N,Jones AE,Johnson SA,Witt DM

    更新日期:2021-01-23 00:00:00

  • The impact of a pulmonary embolism response team on the efficiency of patient care in the emergency department.

    abstract::The concept of a pulmonary embolism response team (PERT) is multidisciplinary, with the hope that it may positively impact patient care, hospital efficiency, and outcomes in the treatment of patients with intermediate and high risk pulmonary embolism (PE). Clinical characteristics of a baseline population of patients ...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-019-01875-0

    authors: Wright C,Elbadawi A,Chen YL,Patel D,Mazzillo J,Acquisto N,Groth C,Van Galen J,Delehanty J,Pietropaoli A,Trawick D,James White R,Cameron P,Gosev I,Barrus B,Kumar NG,Cameron SJ

    更新日期:2019-08-01 00:00:00

  • Hyperhomocysteinemia in patients with pulmonary embolism is associated with impaired plasma fibrinolytic capacity.

    abstract::Hyperhomocysteinemia (HHcy) affects haemostasis and shifts its balance in favour of thrombosis. In vitro and in vivo studies suggested that HHcy may impair fibrinolysis either by influencing the plasma levels of fibrinolytic factors or by altering the fibrinogen structure. We investigated the influence of mild HHcy le...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章

    doi:10.1007/s11239-013-0981-1

    authors: Cellai AP,Lami D,Antonucci E,Liotta AA,Rogolino A,Fedi S,Fiorillo C,Becatti M,Cenci C,Marcucci R,Abbate R,Prisco D

    更新日期:2014-07-01 00:00:00

  • Bleeding risk factors associated with argatroban therapy in the critically ill.

    abstract::Argatroban is a parenteral direct thrombin inhibitor labeled for anticoagulation in patients with confirmed or suspected heparin-induced thrombocytopenia in the United States. Currently there are no studies evaluating bleeding risk factors in Intensive Care Unit patients.To determine bleeding risk factors associated w...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章

    doi:10.1007/s11239-012-0758-y

    authors: Doepker B,Mount KL,Ryder LJ,Gerlach AT,Murphy CV,Philips GS

    更新日期:2012-11-01 00:00:00

  • Acute Myocardial Infarction and the Role of Aspirin, Heparin, and Warfarin.

    abstract::Acute myocardial infarction is initiated by plaque disruption of a fatty plaque with a thin fibrous cap which has been infiltrated by macrophages. The macrophages are attracted and stimulated by oxidized lipids to secrete metalloproteinases which dissolve collagen and arterial wall matrix and to synthesize tissue fact...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/BF01060732

    authors: Chesebro JH,Badimon JJ,Hassinger NL,McBane RD,Fuster V V

    更新日期:1995-01-01 00:00:00

  • Magnesium Therapy for Acute Myocardial Infarction.

    abstract::The use of magnesium therapy for acute myocardial infarction remains controversial despite recent clinical trials such as ISIS-4. Magnesium has numerous beneficial effects in the setting of myocardial infarction, including inhibitory effects on platelet aggregation. Clinical trials of magnesium therapy for myocardial ...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/BF01064375

    authors: Rabbani LE

    更新日期:1995-01-01 00:00:00

  • The effect of the REG2 Anticoagulation System on thrombin generation kinetics: a pharmacodynamic and pharmacokinetic first-in-human study.

    abstract::The REG2 Anticoagulation System consists of pegnivacogin, a subcutaneously administered aptamer factor IXa inhibitor, and its intravenous active control agent, anivamersen. Its effect on thrombin generation is unknown. A prospectively designed thrombin generation study was conducted within the phase 1 ascending dose s...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s11239-014-1081-6

    authors: Vavalle JP,Rusconi CP,Zelenkofske S,Wargin WA,Ortel TL,Alexander JH,Povsic TJ,Becker RC

    更新日期:2014-10-01 00:00:00

  • Thrombolytic therapy in pregnancy.

    abstract::Pregnancy due to its physiological changes is a procoagulant state. The rate of cardiac valve prosthesis thrombosis, deep venous thrombosis and pulmonary embolism are all increased. Thrombolytic therapy with tissue plasminogen activator (rt-PA) is an approved therapy for ischemic stroke, myocardial infarction, pulmona...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-006-5709-z

    authors: Leonhardt G,Gaul C,Nietsch HH,Buerke M,Schleussner E

    更新日期:2006-06-01 00:00:00

  • Interhospital transfer on intravenous thrombolysis in patients with acute ischemic stroke in three chinese municipal stroke centers.

    abstract::We included acute ischemic stroke (AIS) patients who received recombinant tissue plasminogen activator (rt-PA) at three stroke centers via either interhospital transfer or direct presentation and compared the clinical outcomes and time metrics to analyze the impact of interhospital transfer on intravenous thrombolysis...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s11239-019-01912-y

    authors: Ding Y,Ji Z,Ma L,Zhai T,Gu Z,Niu J,Liu Y

    更新日期:2019-11-01 00:00:00

  • Strategies and outcomes of periprocedural bridging therapy with low-molecular-weight heparin in patients with mechanical heart valves.

    abstract::Patients with mechanical heart valves (MHV) undergoing invasive procedures often receive periprocedural bridging with low-molecular-weight heparin (LMWH). The bridging strategies used in real-life and the predictors for bleeding and thrombosis are not well studied. We retrospectively assessed patients with MHV that un...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1007/s11239-015-1216-4

    authors: Schulman JM,Majeed A,Mattsson E,Schulman S,Holmström M,Ågren A

    更新日期:2015-11-01 00:00:00

  • Designing and implementing effective venous thromboembolism prevention protocols: lessons from collaborative efforts.

    abstract::Hospital acquired venous thromboembolism (VTE) is a major source of morbidity and mortality, yet proven prevention measures are often underutilized. The lack of a validated VTE risk assessment model, difficulty integrating VTE risk assessment and prevention protocols into the routine process of care, and the lack of s...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-009-0405-4

    authors: Maynard G,Stein J

    更新日期:2010-02-01 00:00:00

  • Patients with perceived high-bleeding risk and computerized decision support for stroke prevention in atrial fibrillation: an AF-ALERT substudy : Piazza: outcomes of high-bleeding risk AF patients.

    abstract::A perceived increased risk of bleeding is one of the most frequent reasons for withholding anticoagulation for stroke prevention in atrial fibrillation (AF). We previously conducted a randomized controlled trial of alert-based computerized decision support to increase prescription of anticoagulation in hospitalized pa...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-020-02296-0

    authors: Piazza G,Hurwitz S,Carroll B,Goldhaber SZ

    更新日期:2020-09-30 00:00:00

  • Renal Vein Thrombosis and Selective Arterial or Venous Thrombolytic Therapy.

    abstract::Background: Renal vein thrombosis (RVT) complicating the nephrotic syndrome is associated with a poor prognosis. Methods/Results: RVT was diagnosed in 12 of 60 patients with a diagnosis of nephrotic syndrome suggested by computed tomography (CT) and subsequently confirmed by selective renal angiography. Fifty patients...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/BF00226414

    authors: Wu ZL,Zhou KR,Liao Lt

    更新日期:1996-01-01 00:00:00

  • Potentiation of thrombus instability: a contributory mechanism to the effectiveness of antithrombotic medications.

    abstract::The stability of an arterial thrombus, determined by its structure and ability to resist endogenous fibrinolysis, is a major determinant of the extent of infarction that results from coronary or cerebrovascular thrombosis. There is ample evidence from both laboratory and clinical studies to suggest that in addition to...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-018-1641-2

    authors: Gorog DA

    更新日期:2018-05-01 00:00:00

  • Exposure to platelets promotes functional properties of endothelial progenitor cells.

    abstract::Recent evidence indicates that endothelial progenitor cells (EPCs) have an important role in the process of repair following vascular injury, and that platelets mediate their recruitment to sites of injury. Platelets and EPCs can interact and bind directly. However, there is limited information on the effect of platel...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-010-0514-0

    authors: Leshem-Lev D,Omelchenko A,Perl L,Kornowski R,Battler A,Lev EI

    更新日期:2010-11-01 00:00:00

  • Sodium-hydrogen exchange and platelet function.

    abstract::On stimulation of platelets with agonists, for example, thrombin, a rapid rise in intracellular pH is observed. This alkalinization is mediated by an increase in transport activity of the Na(+)/H(+) exchanger isoform NHE1. In addition to this Na(+)/H(+) exchange mechanism, platelets express bicarbonate/chloride exchan...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1023/a:1008986329267

    authors: Rosskopf D

    更新日期:1999-07-01 00:00:00

  • Mitochondria and chronic effects of cancer therapeutics: The clinical implications.

    abstract::One of the major mechanisms of action of chemo-radiation is to induce cellular senescence, which exerts crucial roles in age-related pathology. The concept of senescence is evolved, and the novel understanding of senescence-associated reprogramming/stemness has emerged. This new concept emphasizes senescence as not on...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-020-02313-2

    authors: Dominic A,Hamilton D,Abe JI

    更新日期:2020-10-20 00:00:00

  • Low incidence of thromboembolism in multiple myeloma patients receiving immunomodulatory drugs; a retrospective single-institution analysis.

    abstract::Anti-platelet agents or anticoagulants are administered for patients with multiple myeloma (MM) receiving immunomodulatory drugs (IMiDs) to prevent thrombotic events (TEs). However, there is a discrepancy between current guidelines and clinical practice in thromboprophylaxis and the varied incidence of TEs depending o...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-019-01809-w

    authors: Takaishi K,Tsukamoto S,Ohwada C,Takeuchi M,Kawasaki Y,Nagai Y,Mishina T,Yamazaki M,Isshiki Y,Kayamori K,Kimura K,Hino Y,Oshima-Hasegawa N,Mitsukawa S,Takeda Y,Mimura N,Iseki T,Nakaseko C,Sakaida E

    更新日期:2019-07-01 00:00:00

  • Mechanisms of venous and arterial thrombosis in heparin-induced thrombocytopenia.

    abstract::Since the reports by Weismann and Tobin in 1958 and Roberts et al. in 1964 called attention to paradoxical thrombosis in patients treated with heparin, the thrombotic aspect of the heparin-induced thrombocytopenia syndrome (HIT) has been emphasized. Yet to this day, the mechanism of thrombosis associated with HIT (HIT...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1023/a:1027372901367

    authors: Walenga JM,Jeske WP,Messmore HL

    更新日期:2000-11-01 00:00:00